**SHEET 2:**

Is the MEAN systemic AREA UNDER THE CURVE Doxorubicin concentration significantly DIFFERENT between chemoembolization (AUClast\_D2) vs intraarterial administration (AUClast\_D1)?

Is the MEAN systemic AREA UNDER THE CURVE Doxorubicin concentration significantly DIFFERENT between chemoembolization (AUClast\_D2) vs intravenous administration (AUClast\_D3)?

Is the MEAN systemic AREA UNDER THE CURVE Doxorubicin concentration significantly DIFFERENT between intraarterial administration (AUClast\_D1) vs intravenous administration (AUClast\_D3)?

Is the MEAN systemic MAXIMUM Doxorubicin concentration significantly DIFFERENT between chemoembolization (Cmax\_D2) vs intraarterial administration (Cmax\_D1)?

Is the MEAN systemic MAXIMUM Doxorubicin concentration significantly DIFFERENT between chemoembolization (Cmax\_D2) vs intravenous administration (Cmax\_D3)?

Is the MEAN systemic MAXIMUM Doxorubicin concentration significantly DIFFERENT between intraarterial administration (Cmax\_D1) vs intravenous administration (Cmax\_D3)?

Is the MEAN s time at which systemic Doxorubicin concentration is last detectable significantly DIFFERENT between chemoembolization (Tlast2) vs intraarterial administration (Tlast1)?

Is the MEAN time at which systemic Doxorubicin concentration is last detectable significantly DIFFERENT between chemoembolization (Tlast2) vs intravenous administration (Tlast3)?

Is the MEAN time at which systemic Doxorubicin concentration is last detectable significantly DIFFERENT between intraarterial administration (Tlast1) vs intravenous administration (Tlast3)?

**SHEET 1:**

Is the MEAN/MEDIAN neutrophil count significantly DIFFERENT between intravenous administration (iv\_neut MEAN/MEDIAN) vs intraarterial administration (ia\_neut MEAN/MEDIAN) of Doxorubicin?

Is the MEAN/MEDIAN neutrophil count significantly DIFFERENT between intraarterial administration (ia\_neut MEAN/MEDIAN) vs chemoembolization (em\_neut MEAN/MEDIAN) of Doxorubicin?

Is the MEAN/MEDIAN neutrophil count significantly DIFFERENT between intravenous administration (iv\_neut MEAN/MEDIAN) vs chemoembolization (em\_neut MEAN/MEDIAN) of Doxorubicin?

Is the MEAN/MEDIAN platelet count significantly DIFFERENT following intravenous administration (iv\_plt MEAN/MEDIAN) vs intraarterial administration (ia\_plt MEAN/MEDIAN) of Doxorubicin?

Is the MEAN/MEDIAN platelet count significantly DIFFERENT following intravenous administration (iv\_plt MEAN/MEDIAN) vs chemoembolization (emb\_plt MEAN/MEDIAN) of Doxorubicin?

Is the MEAN/MEDIAN platelet count significantly DIFFERENT following intraarterial administration (ia\_plt MEAN/MEDIAN) vs chemoembolization (emb\_plt MEAN/MEDIAN) of Doxorubicin?

Is the MEAN/MEDIAN number of days bloodwork is performed post-treatment significantly DIFFERENT between intraarterial administration (D\_PostIA MEAN/MEDIAN ) vs chemoembolization (D\_PostEm MEAN/MEDIAN) vs intravenous administration (D\_PostIV MEAN/MEDIAN)?

**SHEET 3:**

Is the MEAN/MEDIAN maximum Doxorubicin concentration significantly DIFFERENT between patients with PES following intraarterial administration (NPSA\_CMa MEAN/MEDIAN) vs patients without PES following intraarterial administration (PSA\_CMa MEAN/MEDIAN)?

Is the MEAN/MEDIAN maximum Doxorubicin concentration significantly DIFFERENT between patients with PES following chemoembolization (NPSE\_CMa MEAN/MEDIAN) vs patients without PES following chemoembolization (PSE\_CMa MEAN/MEDIAN)?

Is the MEAN/MEDIAN systemic AREA UNDER THE CURVE Doxorubicin concentration significantly DIFFERENT between patients with PES following intraarterial administration (NPSA\_AUC MEAN/MEDIAN) vs patients without PES following intraarterial administration (PSA\_AUC MEAN/MEDIAN)?

Is the MEAN/MEDIAN systemic AREA UNDER THE CURVE Doxorubicin concentration significantly DIFFERENT between patients with PES following chemoembolization (NPSE\_AUC MEAN/MEDIAN) vs patients without PES following chemoembolization (PSE\_AUC MEAN/MEDIAN)?